A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Followed by carboplatin/Paclitaxel vs Chemotherapy, Both in Combination with Pembrolizumab as Neoadjuvant Therapy for Triple-Negative Breast Cancer (TNBC) or Hormone Receptor-low positive/HER2-negative Breast Cancer (TROFUSE-032)
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Sponsor
Merck Sharp & Dohme LLC
Enrollment Form
This study is currently enrolling.